Search Our Scientific Publications & Authors

Pathology 2018 10 8;50(6):668-670. Epub 2018 Aug 8.

Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan; Department of Pathology, School of Medicine, Taipei Medical University and National Taiwan University, Taipei, Taiwan.

Acta Med Indones 2018 Apr;50(2):104-109

Division of Hematology and Medical Oncology, Dharmais Hospital National Cancer Center, Jakarta, Indonesia.

Background: the expression of CD30, CD15, CD50, and PAX5 are used to help in confirming diagnosis of HL and sALCL; however data on the proportion of these markers have not been available. The study was aimed to identify the proportion of CD30, CD15, CD50 and PAX5 expressions and characteristics of patients with HL and sALCL at Dharmais National Cancer Center Hospital between 2005 and 2015.

Methods: a retrospective observational study was conducted using data from medical records and histopathological results of HL and sALCL adult patients who sought treatment at the hospital between 2005 and 2015. Read More

Acta Med Indones 2018 Apr;50(2):93-95

Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Hodgkin lymphoma is a cancer that can be cured using standard chemotherapy with or without radiation. Although it accounts for only 0.6% of all malignancy worldwide, but it usually affects young adults with median age of 38 years. Read More

Ann Dermatol Venereol 2018 Jun - Jul;145(6-7):433-438. Epub 2018 Apr 17.

Service de dermatologie et d'allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Faculté de médecine, Sorbonne université, 75013 Paris, France. Electronic address:

Background: Fingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described. Read More

J Clin Pathol 2018 Sep 17;71(9):795-801. Epub 2018 Apr 17.

Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Aim: CD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in DLBCLs and try to find the correlated influences. Read More

Clin Exp Dermatol 2018 Jul 23;43(5):585-588. Epub 2018 Feb 23.

Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Hospital Oberhausen, University Witten-Herdecke, Oberhausen, Germany.

CD30-positive primary cutaneous anaplastic large cell lymphoma (C-ALCL) is an indolent type of cutaneous lymphoma with favourable clinical prognosis. Pseudocarcinomatous hyperplasia (PCH) is a rare benign epithelial condition that can resemble invasive squamous cell carcinoma both clinically and histopathologically. PCH predominantly occurs in CD30-positive lymphoproliferative disorders. Read More

J Vet Diagn Invest 2018 May 19;30(3):455-458. Epub 2018 Feb 19.

Departments of Pathobiology and Population Sciences (Pittaway, Szladovits, Suárez-Bonnet, Priestnall), The Royal Veterinary College, University of London, North Mymms, United Kingdom.

Anaplastic large-cell lymphoma or null-cell lymphoma is a clinical entity reported in people, classified according to the unique appearance of large pleomorphic cells that express CD30. Null-cell lymphoma has also been described in dogs when neither CD3 nor CD79α is expressed by the tumor. We describe a case of lymphoma in the dog in which neoplastic cells did not express routine B- or T-lymphocyte markers on flow cytometry or immunohistochemistry; however, cells immunohistochemically labeled for CD30. Read More

BMC Cancer 2018 02 1;18(1):122. Epub 2018 Feb 1.

Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Background: Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or refractory HL or ALCL suggests efficacy of brentuximab vedotin (SGN-35). Pediatric patients should be given medicines that have been appropriately evaluated for their use. Read More

Mol Oncol 2018 03 26;12(3):339-355. Epub 2018 Jan 26.

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

CD30 is a 120-kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL). CD30-targeted treatment with antibody-drug conjugates (ADCs) can lead to promising clinical benefit. Read More

J Clin Exp Hematop 2017 ;57(3):120-142

Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research.

Anaplastic large cell lymphoma (ALCL) was first described in 1985 as a large-cell neoplasm with anaplastic morphology immunostained by the Ki-1 antibody, which recognizes CD30. In 1994, the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion receptor tyrosine kinase was identified in a subset of patients, leading to subdivision of this disease into ALK-positive and -negative ALCL in the present World Health Organization classification. Due to variations in morphology and immunophenotype, which may sometimes be atypical for lymphoma, many differential diagnoses should be considered, including solid cancers, lymphomas, and reactive processes. Read More

Zhonghua Bing Li Xue Za Zhi 2017 Oct;46(10):708-713

Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

To investigate the clinicopathologic characteristics of neoplastic cell-rich mixed cellularity classical Hodgkin lymphoma(MCCHL-R) and to compare the prognosis with typical mixed cellularity classic Hodgkin lymphoma(MCCHL). Fifty-four patients with MCCHL-R(the tumor cells >10%) and 65 patients with typical MCCHL identified from 1 721 Hodgkin lymphomas were reviewed to compare the clinicopathological characteristics including morphologic and immunophenotypic features, EBV infection status, clinical therapy and overall survival. The median age of the patients of MCCHL-R was 28. Read More

Aesthet Surg J 2017 Sep;37(8):NP83-NP87

Department of Plastic, Reconstructive, and Hand Surgery, Maastricht University Medical Center, Maastricht, the Netherlands. Department of Plastic, Reconstructive, and Hand Surgery, VU University Medical Center, Amsterdam, the Netherlands. Department of Oncology, Netherlands Cancer Institute, Amsterdam. Dutch Nationwide Network and Registry of Histo- and Cytopathology, Houten, the Netherlands. Division of Epidemiology, Netherlands Cancer Institute, Amsterdam. Department of Plastic, Reconstructive, and Hand Surgery, MST, Enschede, the Netherlands, Dutch Society of Plastic Surgery. Division of Plastic, Reconstructive, and Hand Surgery, Maastricht University Medical Center. Department of Pathology, VU University Medical Center. Department of Plastic, Reconstructive, and Hand Surgery, VU University Medical Center. Center of Expertise on Gender Dysphoria at the VU University Medical Center. Division of Pathology, VU University Medical Center. Dutch BIA-ALCL Consortium.

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare but serious complication in patients with breast implants, Patients are at risk of BIA-ALCL whether they receive breast implants for cosmetic reasons or for reconstructive purposes after surgery for breast cancer or prophylactic mastectomy. During the past decade, an increased number of reports have addressed BIA-ALCL. Herein, we describe BIA-ALCL in a transgender woman. Read More

Blood Cancer J 2017 09 8;7(9):e603. Epub 2017 Sep 8.

Department of Haematology, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.

CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Read More

Expert Opin Biol Ther 2017 12 28;17(12):1503-1510. Epub 2017 Aug 28.

a Unit of Dermatology, Department of Medicine , University of Padua , Padua , Italy.

Introduction: Cutaneous T-cell lymphomas (CTCLs) comprise of a group of rare and heterogeneous skin lymphoproliferative disorders derived from skin resident T cells. Treatment of CTCLs is based on skin-directed approaches and/or systemic therapies. Advanced CTCLs are difficult to treat with the currently available treatments as they generally fail to obtain prolonged clinical remission. Read More

J Clin Invest 2017 Sep 14;127(9):3462-3471. Epub 2017 Aug 14.

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, Texas, USA.

Background: Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. Read More

Future Oncol 2017 Nov 14;13(27):2405-2411. Epub 2017 Aug 14.

Dermatology - University Hospitals Birmingham NHS Foundation Trust, University Hospital Birmingham, Birmingham, B15 2TH, UK.

CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Read More

Int J Dermatol 2017 Dec 1;56(12):1400-1405. Epub 2017 Aug 1.

Department of Dermatology, University of Texas Southwestern, Dallas, TX, USA.

Background: The utility of brentuximab vedotin (BV) in CD30 systemic lymphomas is established, however evidence for treating primary cutaneous lymphoma remains limited. This study aimed to evaluate BV in treating CD30 transformed mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (PC-ALCL).

Methods: A literature review was conducted, and we analyzed data from published trials and case reports obtained via search of Ovid-MEDLINE and PubMed databases. Read More

PLoS One 2017 17;12(7):e0181097. Epub 2017 Jul 17.

Department of Clinical and Molecular Medicine, Sapienza University, Cytology Unit, Sant'Andrea Hospital, Roma, Italy.

Late breast implant seroma may be the presentation of a breast implant-associated anaplastic large cell lymphoma (BI-ALCL), which claims for a prompt recognition. However, BI-ALCL diagnosis on fine-needle aspiration (FNA) might be challenging for pathologists lacking experience with peri-implant breast effusions. Sixty-seven late breast implant seromas collected by FNA from 50 patients were evaluated by Papanicolaou smear stain and immunocytochemistry on cell blocks. Read More

Ann Diagn Pathol 2017 Jun 10;28:54-59. Epub 2017 Feb 10.

Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY 10065, USA. Electronic address:

Background: Negative immunoregulatory checkpoints impede effective immune responses to tumor and reduce the action of anticancer agents. One such example is programmed death marker-1 (PD-1), an inhibitory signaling receptor expressed on activated and regulatory T-cells. PD-1 expression was reported in a few reports, but the expression profile of PD-1 and mycosis fungoides (MF) remains largely to be characterized. Read More

J Cutan Pathol 2017 Aug 13;44(8):703-712. Epub 2017 Jun 13.

Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.

CD8-positive, CD30-positive cutaneous lymphoproliferative disorders constitute a rare subset of T-cell lymphoproliferative conditions, including variants of primary cutaneous anaplastic large cell lymphoma (ALCL), mycosis fungoides, lymphomatoid papulosis type D, cutaneous gamma-delta T-cell lymphoma and cutaneous peripheral T-cell lymphoma. These entities share overlapping clinical, histopathologic and immunophenotypic features, presenting both a clinical and pathological diagnostic challenge. Presented here is a 73-year-old man with a disseminated, indolent CD30+, CD8+ cutaneous lymphoproliferative disorder with overlapping clinical and histopathological features of both mycosis fungoides and primary cutaneous ALCL, as well as features of lymphomatoid papulosis. Read More

Mult Scler Relat Disord 2017 Apr 6;13:119-121. Epub 2017 Mar 6.

B' Department of Neurology, AHEPA University Hospital, Kyriakidi Str., 54636 Thessaloniki, Greece.

Central nervous system involvement is an uncommon complication of systemic non-Hodgkin lymphomas. The majority of these cases concern B-cell lymphomas. We report a case of systemic T-cell anaplastic large cell lymphoma CD30+ ALK- with CNS involvement at the time of diagnosis and unusual MRI characteristics resembling acute disseminated encephalomyelitis. Read More

Crit Rev Oncol Hematol 2017 May 27;113:8-17. Epub 2017 Feb 27.

Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States.

Background: CD30 (Ki-1) is a cell membrane protein derived from the tumor necrosis factor (TNF) receptor family. The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen. Read More

Aesthet Surg J 2017 07;37(7):771-775

Jersey Shore University Medical Center, Neptune, NJ.

The objective was to analyze and discuss the implications of a nonmalignant CD30+ late seroma. Methods included collection of seroma fluid and peripheral blood from a patient with a late seroma 22 years after initial breast reconstruction. A panel of 24 monoclonal antibodies was used to detect T-cell receptor Vβ regions present on ~70% of normal human peripheral blood T lymphocytes. Read More

J Cutan Pathol 2017 Jun 25;44(6):570-577. Epub 2017 Apr 25.

Department of Pathology, Stanford University School of Medicine, Stanford, California.

Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease. CD30+ LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides. Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms. Read More

J Natl Cancer Inst 2017 02 31;109(2). Epub 2016 Dec 31.

Memorial Sloan-Kettering Cancer Center, New York, NY , USA.

Peripheral T-cell lymphomas (PTCLs) are uncommon, heterogeneous, and aggressive non-Hodgkin's lymphomas. Despite progress in the last several years resulting in a deeper understanding of PTCL biology and pathogenesis, there is currently no accepted single standard of care for newly diagnosed patients, and for those with relapsed or refractory disease, prognosis is dismal. The National Cancer Institute convened a Clinical Trials Planning Meeting to advance the national clinical trial agenda in lymphoma. Read More

Semin Diagn Pathol 2017 Jan 29;34(1):22-35. Epub 2016 Nov 29.

Kempf und Pfaltz, Histologische Diagnostik, Zürich, Switzerland; Department of Dermatology, University Hospital Zurich, CH-8091, Zurich, Switzerland. Electronic address:

Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ T-LPD) represent a spectrum encompassing lymphomatoid papulosis (LyP), primary cutaneous anaplastic large-cell lymphoma (pcALCL) and borderline lesions. They share the expression of CD30 as a common phenotypic marker. They differ however in their clinical presentation, the histological features and clinical course. Read More

Expert Rev Hematol 2017 Jan 21;10(1):29-37. Epub 2016 Dec 21.

a Hematology & Oncology , University of Alabama at Birmingham , Birmingham , AL , USA.

Introduction: CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma. Areas covered: CD30 testing is essential in diagnosis of classical HL and ALCL, and expression can also be seen in other lymphoma subtypes. Read More

Am J Pathol 2017 Jan 19;187(1):163-175. Epub 2016 Nov 19.

Department of Hematology, School of Medicine, Kitasato University, Minami-ku, Sagamihara, Kanagawa, Japan; Division of Hematology, Department of Laboratory Sciences, School of Allied Health Sciences, Kitasato University, Minami-ku, Sagamihara, Kanagawa, Japan. Electronic address:

Previous studies report deregulation of multiple signaling pathways in classic Hodgkin lymphoma (cHL) cells. However, the mechanisms of how these pathways are integrated are not fully understood. Herein, we show involvement of cHL hallmark antigen CD30 in this process. Read More

J Cutan Pathol 2016 Nov 26;43(11):1041-1044. Epub 2016 Aug 26.

Department of Pathology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.

Lymphomatoid papulosis (LyP) is classified as a CD30+ primary cutaneous lymphoproliferative disease. The phenotypic variability along the spectrum of CD30+ lymphoproliferative diseases is highlighted by the distinct histologic subtypes of LyP types A, B, C, and the more recently described types D, E, and F. We report the case of an elderly woman with a clinical presentation and histopathologic findings consistent with LyP, whose atypical CD30+ infiltrate uniquely demonstrated a spindle-cell morphology. Read More

Eur J Dermatol 2017 Feb;27(1):68-69

Department of Dermatology, Nara Medical University School of Medicine, 840 Shijo, Kashihara, Nara 634-8522, Japan.

Anticancer Agents Med Chem 2017 ;17(7):886-895

Division of Hematology, University of Siena, Siena, Italy.

The CD30 antigen is strongly expressed on neoplastic cells in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL) and other hematologic malignancies (such as DLBCL and cutaneous TCL), while is almost undetectable on healthy tissues, representing an ideal immunotherapeutic target. Since unconjugated anti-CD30 antibody (SGN-30) demonstrated limited clinical activity, researchers' effort aimed to create an antibody-drug conjugate (ADC), leading to discovery of SGN-35 (brentuximab vedotin), in which an anti-CD30 antibody is linked to the antimitotic agent monomethyl auristatin E (MMAE). In the first phase I study in CD30+ hematologic malignancies (the majority of patients with HL), the maximum tolerated dose was fixed respectively at 1. Read More

Br J Dermatol 2016 08;175(2):246-7

Servicio de Dermatología, Hospital 12 de Octubre, Universidad Complutense, Instituto i + 12, Madrid, Spain.

J Cutan Pathol 2016 Dec 15;43(12):1161-1166. Epub 2016 Sep 15.

Department of Pathology, Section of Dermatopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma characterized by strong and uniform expression of CD30. Brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate has been approved by the U.S. Read More

Clin Lymphoma Myeloma Leuk 2016 08 10;16(8):429-33. Epub 2016 May 10.

Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA.

Background: US Food and Drug Administration approval of brentuximab vedotin for treatment of CD30-positive relapsed/refractory lymphomas, including classical Hodgkin lymphoma and anaplastic large cell lymphoma, initiated significant interest in researching CD30 expression in other therapy-resistant or relapsed lymphomas. We evaluated CD30 expression in 116 cases of aggressive B-cell lymphomas diagnosed at Penn State Milton S. Hershey Medical Center between 2000 and 2012 with the purpose of assessing the benefit of treatment with brentuximab. Read More

J Dtsch Dermatol Ges 2016 Aug;14(8):767-82

Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston Texas, U.S.A.

Primary cutaneous CD30(+) lymphoproliferative disorders are the second most common group of cutaneous T-cell lymphomas (CTCL) and include lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Both disease entities share overlapping clinical, histopathological, and molecular features, thus representing a spectrum of cutaneous CD30(+) lymphoproliferative disorders. LyP may be distinguished from cALCL by clinicopathological correlation. Read More

Expert Rev Hematol 2016 Aug 14;9(8):767-80. Epub 2016 Jul 14.

a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.

Introduction: Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has been approved in relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT) and anaplastic large-cell lymphoma (ALCL). Beyond these consolidated indications, BV has been tested in a number of different settings with promising results, leading for example to the recent approval as a consolidation after ASCT in high-risk HL patients.

Areas Covered: Main emerging areas of clinical investigation of BV include the use as a single-agent or in combination with bendamustine in first-salvage therapy of HL (bridge to ASCT), in the frontline setting in combination with AVD chemotherapy in HL and with CHP in ALCL, in relapsed or refractory cutaneous T-cell lymphomas and finally in diffuse large B-cell lymphomas (DLBCL) expressing CD30. Read More

J Drugs Dermatol 2016 Jul;15(7):894-5

Monoclonal antibody therapy is a new innovation in cancer therapy. Binding of monoclonal antibodies to tumor cells facilitates their destruction by the immune system. Tumor cells with mutated target antigens may escape detection by monoclonal antibodies and exhibit a selective growth advantage. Read More

Rinsho Ketsueki 2016 05;57(5):634-7

Department of Hematology and Oncology, Dokkyo Medical University School of Medicine.

A 59-year-old woman with anaplastic large cell lymphoma (ALCL), ALK-negative, was treated with brentuximab vedotin (BV) against relapse after 6 regimens of systemic chemotherapy and radiation. Despite achieving an initial response, skin lesions worsened after 11 courses. A skin biopsy after the development of resistance to BV confirmed loss of CD30 expression by the tumor cells, suggesting a possible cause of resistance. Read More

Mult Scler 2016 12 26;22(14):1888-1890. Epub 2016 Apr 26.

Department of Dermatology and Venereology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany.

Background: The appearance of solid tumors und lymphomas during treatment with fingolimod was observed in studies and has been described in case reports.

Objective: To report a case of primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis (MS) with fingolimod.

Methods: Case study. Read More

Blood 2016 07 4;128(1):141-3. Epub 2016 May 4.

Department of Dermatology, and.

Ann Emerg Med 2016 May;67(5):677-83

Department of Emergency Medicine, University of Texas Southwestern Medical School, Dallas, TX.

J Cutan Pathol 2016 Jul 8;43(7):579-88. Epub 2016 May 8.

Kempf and Pfaltz Histologische Diagnostik, Zürich, Switzerland.

Background: The tumor microenvironment is essential for tumor survival, growth and progression. There are only a few studies on the tumor microenvironment in cutaneous CD30-positive lymphoproliferative disorders.

Methods: We assessed the composition of the tumor microenvironment using immunohistochemistry studies in skin biopsies from cases diagnosed with lymphomatoid papulosis (LyP: 18 specimens), primary cutaneous anaplastic large-cell lymphoma (PC-ALCL: 8 specimens), and reactive diseases harboring CD30-positive cells (18 specimens). Read More

Br J Dermatol 2016 Aug 13;175(2):325-33. Epub 2016 Jul 13.

Université Paris-Diderot, Sorbonne Paris Cité, Paris, 75010, France.

Background: KIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sézary syndrome. Anti-KIR3DL2 targeted antibody therapy has shown potent activity in preclinical models for these diseases.

Objectives: To examine the expression of KIR3DL2 and its potential use as a therapeutic target in patients with primary cutaneous anaplastic large-cell lymphoma (pcALCL), the most aggressive cutaneous CD30(+) lymphoproliferative disease. Read More

Am J Dermatopathol 2016 May;38(5):388-92

*Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; †Department of Dermatology, Mayo Clinic, Rochester, MN, Dr. Cohen is now affiliated with the Department of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Michael E. DeBakey Veterans Affairs Hospital, Houston, TX (As of/After July 1, 2015); ‡Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN; and §Departments of Laboratory Medicine and Pathology, and Dermatology, Mayo Clinic, Rochester, MN.

CD30-positive cutaneous lymphoproliferative disorders, a group of T-cell neoplasms, including lymphomatoid papulosis (LyP) and cutaneous anaplastic large cell lymphoma, require careful clinicopathologic correlation for diagnosis. An association between LyP and the development of a second hematolymphoid malignancy has been established in the literature. LyP has also been reported with systemic amyloidosis, but no such reports have documented coexisting cutaneous amyloid deposition with LyP to our knowledge. Read More

Ann Hematol 2016 Apr 2;95(5):847-9. Epub 2016 Mar 2.

Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China.

Am J Dermatopathol 2016 Jan;38(1):e1-10

Departments of *Dermatology and Cutaneous Biology; †Surgery, Thomas Jefferson University, Philadelphia, PA; and ‡Dermatologist and Dermatopathologist, Bryn Mawr Skin and Cancer Institute, Main Line Health, Bryn Mawr, PA.

Lymphomatoid papulosis (LyP) is an uncommon CD30 lymphoproliferative disorder with a relatively excellent prognosis. Ten to twenty percent of cases, however, are associated with a lymphoma, typically systemic or cutaneous anaplastic large cell lymphoma, mycosis fungoides, or Hodgkin lymphoma. Subtypes divide LyP into infiltrate-descriptive categories along a spectrum of histological manifestation. Read More

Dermatol Online J 2016 Oct 15;22(10). Epub 2016 Oct 15.

Medical School, University of California, San Diego, CA, USA.

Background CD30+ lymphoproliferative disorders are rare and may feature a wide variety of presentations that mimic other conditions. Purpose A man with metastatic papillary thyroid carcinoma to skin who subsequently developed cutaneous anaplastic large cell lymphoma is described. Methods The PubMed medical database was used to search the following terms separately and in combination: ALCL, anaplastic large cell lymphoma ALCL, cutaneous anaplastic large cell lymphoma CALCL, cutaneous t-cell lymphoma CTCL, large t-cell lymphoma LTCL, lymphoproliferative, lymphomatoid papulosis LyP, mimic, papillary, thyroid cancer. Read More

Front Biosci (Elite Ed) 2016 Jan 1;8:61-71. Epub 2016 Jan 1.

Department of Pathology and Cytology, Karolinska University Hospital and Karolinska Institute, Radiumhemmet, Stockholm, Sweden SE-17176.

ALK+ anaplastic large cell lymphoma (ALCL). frequently carries the t(2;5).(p23;q35). Read More

Clin Lymphoma Myeloma Leuk 2016 Feb 1;16(2):e15-9. Epub 2015 Dec 1.

Department of Dermatology and Dermatopathology, University of Texas MD Anderson Cancer Center, Houston, TX.